Drugs / AGEN1571
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05377528 | Jul 2022 → Dec 2024 | neoplasm | Agenus Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGEN1571 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05377528 ↗ |
| Action | Inhibit | “A fully human monoclonal immunoglobulin-like transcript antagonist antibody” NCT05377528 ↗ |
| Modality | Monoclonal antibody | “A fully human monoclonal immunoglobulin-like transcript antagonist antibody” NCT05377528 ↗ |
| Route | Intravenous | “administered intravenously” NCT05377528 ↗ |